The Centers for Disease Control and Prevention's vaccine advisory committee is set to meet for the first time since Health ...

The Centers for Disease Control and Prevention's vaccine advisory committee is set to meet for the first time since Health ...

By Chandni Shah, Mariam Sunny and Christy Santhosh (Reuters) -The U.S. Food and Drug Administration has approved Moderna's next-generation COVID-19 vaccine for everyone aged 65 and above, the ...

The U.S. Food and Drug Administration on Thursday expanded the use of Moderna's respiratory syncytial virus vaccine to a lower group of adults aged 18 to 59 years at increased risk for disease.

The Food and Drug Administration expanded the approval of Moderna’s RSV vaccine on Thursday, extending the license to include adults ages 18 to 59 who are at high risk of severe illness if they ...

Last June, ACIP unanimously recommended that all adults ages ≥75 years and adults ages 60 to 74 years who are at increased risk of severe RSV disease receive a single dose of RSV vaccine; the ...

For older adults who express more confidence in vaccine safety than younger groups, the past few months have brought welcome ...

The meeting, scheduled for June 25-26, will review existing data and vote on RSV and influenza vaccines, along with thimerosal, a preservative used in vials of medicines and vaccines. Below are ...

RSV hospitalizes 15,000-20,000 U.S. adults aged 50-59 annually. Competing vaccines from Pfizer Inc. PFE and GSK plc GSK also target similar demographics, intensifying market competition amid ...

"First, they provide evidence of vaccine protection against RSV-associated hospitalization, of which an estimated 60,000 to 160,000 occur annually among U.S. adults aged 65 years and older.

mNEXSPIKE - The next-generation COVID-19 vaccine was approved for aged 65 and above in May 2025. Spikevax, Moderna's first COVID-19 vaccine, received its initial FDA approval in January 2022.